MedTrace Logo

Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS)

NCT03528434 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2021-02-09

No results posted yet for this study

Summary

A randomized double-blinded placebo-controlled trial of zinc to reduce the incidence of severe or invasive infections in Ugandan children with sickle cell anemia (SCA).

Conditions

Interventions

DIETARY_SUPPLEMENT

Zinc

10mg dispersible zinc sulfate tablet

OTHER

Placebo

Dispersible tablet with inert ingredients, identical to zinc in appearance

Sponsors & Collaborators

  • Children's Hospital Medical Center, Cincinnati

    collaborator OTHER

  • Makerere University

    collaborator OTHER

  • Jinja Regional Referral Hospital

    collaborator UNKNOWN

  • Université de Montréal

    collaborator OTHER

  • Indiana University

    lead OTHER

Principal Investigators

  • Chandy C. John, MD · Indiana University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-14
Primary Completion
2020-11-23
Completion
2020-11-23

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03528434 on ClinicalTrials.gov